Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Cellular Immunotherapy for Multiple Myeloma

Rosenblatt, Jacalyn, MD; Avigan, David, MD

doi: 10.1097/PPO.0000000000000356
Review Articles
Buy
SDC

Cellular immunotherapy for myeloma has the unique potential both to potently kill the malignant clone and to evoke a memory response to protect from relapse. Understanding the complex interactions between the malignant clone and the microenvironment that promote immune escape is critical to evoke effective antimyeloma immunity. Tremendous progress has been made in the area of cancer vaccines and adoptive T-cell therapy in recent years. Careful study of the mechanisms of response and of immune escape will be critical to developing novel combination therapies and ultimately to improve outcomes for patients with myeloma.

Beth Israel Deaconess Medical Center, Boston, MA.

The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Reprints: Jacalyn Rosenblatt, MD 330 Brookline Ave, Boston MA 02215. E-mail: jrosenb1@bidmc.harvard.edu.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.